Alterity Therapeutics Limited
- ATHE
- NASDAQ
- Biotechnology
- Neurodegenerative Disease Therapeutics
- Clinical-Stage Biotech
$2.62
Today −3.68%Quote Oct 16, 2026, 08:00 PM UTC
−30.13%over the last month
Max drawdown −33.0%From 1-month high −33.0%3 months −44.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$569.9M
Quote Oct 16
Next earnings
Mar 4
Expected, not confirmed
Analyst target
$8.00
+205.3% from here
Floor
$2.61
0.2% below price
Where the price sits
8 analysts
Analyst range, low to high
$2.00$12.00
- Price $2.62
- Resistance $2.75
- Consensus $8.00
The price is just above its floor. Analysts' average target sits about 205% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ATHEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
11